StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Pulmicort (budesonide) — Worldwide product sales by Quarter

Pulmicort (budesonide) — Worldwide product sales ($M) ($M)

QuarterlyAnnual

AstraZeneca Pulmicort (budesonide) — Worldwide product sales: $120M in Q2 2026, up 13.2% from a year earlier.

Latest, Q2 2026
120
Period ended Jun 30, 2026
Change on a year earlier
+13.2%
106 in Q2 2025
History
42 quarters
Since Q1 2016
Sources
27
Documents cited below

Where the Q2 2026 figure comes from

“|| Pulmicort | 120 | | 13 | | 9 | | 2 | | 11 | | 97 | | 20 | | 15 | | 14 | | ( 5 ) | | ( 9 ) | | 7 | | ( 17 ) | | ( 17 )”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPulmicort (budesonide) — Worldwide product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026120+13.2%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 2026149-5.7%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 2025161-1.8%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 202593-32.6%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 2025106-31.6%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 2025158-29.5%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 2024164-25.1%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 2024138-6.8%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 2024155+25.0%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 2024224+1.4%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 2023219+31.9%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 2023148+2.1%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 2023124+6.9%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 2023221+1.8%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 2022166-33.1%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 2022145-33.2%Form 6-K FY2022Q3 Earnings Release ↗

Breakdown

What makes up pulmicort (budesonide) — Worldwide product sales

Cite this data

StockData. (2026). AstraZeneca Pulmicort (budesonide) — Worldwide product sales ($M), quarterly Q1 2016–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-pulmicort-world

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.